Reviewer’s report

Title: Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies

Version: 3 Date: 26 December 2013

Reviewer: Esther Garcia Gil

Reviewer’s report:

Minor essentials:
Background and objectives:
- Glycopyrronium has only been approved as a once daily drug in Europe. There are ongoing phase 3 studies with twice daily administration, which were required by the FDA. Therefore, the sentence about glycopyrronium to be an approved twice daily b2-agonist is not appropriate.
- Olodaterol has been approved in a few European countries, if I'm not wrong in the Netherlands. Please, check it for accuracy about the statement related to this drug to be in late stage development.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I work in a pharmaceutical company focus in the development of respiratory drugs, including anticholinergic and b-2agonists drugs.